Friday, November 05, 2010 9:17:23 AM
Nov 04, 2010
Dengue Fever Vaccine In Final Phase – A vaccine against the dengue fever created by Sanofi Pasteur’s Sanofi-Aventis has entered the final phase of its development and will be hitting the market very soon.
Earlier today the French pharmaceutical group revealed that they have just begun a Phase III clinical trial in Australia in order to validate the effectiveness of the vaccine against all four serotypes of the dengue virus which affects 60 to 200 million people worldwide each year.
At the end of this phase, the vaccine will be marketed and it could be a protection against the disease that is spreading more and more especially in the Caribbean.
The company went on to say the results and details of the Australian study will be revealed at the 59th conference of the The American Society of Tropical Medicine and Hygiene (ASTMH) which is being held in Atlanta from November 3 through November 7, 2010.
According to a Sanofi Pasteur press release:
Previous clinical studies have been conducted in adults and children in the United States, Asia and Latin America were very conclusive.The world’s 3rd largest pharmaceutical company went on to explain, that after receiving three doses of vaccine, the participants presented an immune response known as “balanced” against the four serotypes of dengue virus.
The dengue hemorrhagic fever was mentioned in numerous media outlets this week after it was revealed that three-time world surfing champion Andy Irons died from dengue fever.
http://is.gd/gKnAU
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM